Ad
related to: lipitor reducing dosage
Search results
Results From The WOW.Com Content Network
Lipid-lowering agents, also sometimes referred to as hypolipidemic agents, cholesterol-lowering drugs, or antihyperlipidemic agents are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins, such as cholesterol, in the blood (hyperlipidemia). The American Heart Association recommends the descriptor ...
Risk factors for statin induced rhabdomyolysis include older age, renal impairment, high dose statins and use of medications that reduce the breakdown of statins (such as CYP3A4 inhibitors) or fibrates. [66] Persistent liver enzyme abnormalities (usually elevated in hepatic transaminases) have been documented. [67]
Statins remain a first-line treatment in familial hypercholesterolemia, [53] although other cholesterol-reducing measures may be required. [55] In people with homozygous deficiencies, statins may still prove helpful, albeit at high doses and in combination with other cholesterol-reducing medications. [56]
Statins help lower cholesterol For this observational study, researchers analyzed data from the U.K. Biobank and Whitehall II study of more than 20,000 adults in the U.K. 70 years and older with ...
Credit not just the weight loss but also the drugs’ ability to reduce contributors to those conditions, including blood sugar, blood pressure, cholesterol, and inflammation. Alzheimer’s Prevention
Comparable to statins and ezetimibe, fibrates are usually well-tolerated with mild adverse reactions, with the exception of gemfibrozil. Some of the more prevalent side effects are minor gastrointestinal disturbances such as abdominal pain and cholithiasis on account of the increased excretion of biliary cholesterol. [23]
In other words, as many as 4 million people in the U.S. who currently take statins for primary prevention — meaning they have not had a cardiovascular event such as a stroke or heart attack ...
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]